Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 14/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599923 | 0.96 | GPR183 (1.00) | GPR183GRM3CYP3A4USP2TSHR | |
| SCHEMBL16599878 | 0.91 | GPR183 (1.00) | GPR183 | |
| SCHEMBL16600181 | 0.90 | GPR183 (0.81) | GPR183GRM3CYP3A4USP2TSHR | |
| SCHEMBL16600078 | 0.87 | GPR183 (1.00) | GPR183 | |
| SCHEMBL16599932 | 0.86 | GPR183 (1.00) | GPR183CYP3A4USP2TSHRCYP2D6 | |
| SCHEMBL16599826 | 0.86 | GPR183 (1.00) | GPR183 | |
| SCHEMBL16600166 | 0.86 | GPR183 (0.92) | GPR183 | |
| SCHEMBL16600134 | 0.86 | GPR183 (1.00) | GPR183 | |
| SCHEMBL16599836 | 0.85 | GPR183 (0.83) | GPR183GRM3CYP3A4USP2TSHR | |
| SCHEMBL16600533 | 0.84 | GPR183 (0.85) | GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196369-B2 | Spirocyclic EBI2 modulators | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-05 | — | — | US | claimed |
| US-10196369-B2 | Spirocyclic EBI2 modulators | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-02-05 | — | — | US | disclosed |
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | Sanford Burnham Prebys Medical Discovery Institute | 2016-06-23 | — | — | US | disclosed |
| WO-2015048567-A1 | SPIROCYCLIC EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | HAVCR2, BIRC2, ESR2 | GPR183 17/4885GRM3 648/4885CYP3A4 4233/4885 |
| US-10196369-B2 | Spirocyclic EBI2 modulators | HAVCR2, BIRC2, ESR2 | GPR183 17/4885GRM3 648/4885CYP3A4 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.